According to FutureWise analysis the market for Granisetron is expected to register a CAGR of 6.42% from 2024-2032.
Granisetron, a serotonin 5-HT3 receptor antagonist, is used as an antiemetic for nausea and vomiting after radiotherapy and chemotherapy. It works by reducing the activity of vagus nerves, which activate the vomiting center in medulla Oblongata. Granisetron, also known as a selective serotonin receptor antagonist (or "serotonin blocking agent"), decreases nausea and vomiting by blocking brain signals telling you to vomit. Granisetron may also block receptors on the blood vessels and heart. Preventing nausea is a way to reduce the risk of cancer for patients undergoing chemotherapy, surgery, pregnant women, and people who just had dental work done. You can also take it by mouth to treat diarrhea due to radiation treatment (to your abdomen) for cancer. Granisetron has few side effects and is well-tolerated. Side effects that have been reported most frequently include headaches, dizziness, constipation, and stomach pain. This drug has not been linked to any drug interactions.
It is broken down by the liver’s cytochrome H450 system, and has very little effect on other drugs that are broken down by this system. Study "An observational, real-world study using Granisetron Transdermal System and Dexamethasone to minimise nausea and vomiting in multiple myeloma patients receiving chemotherapy-mobilization. Security and efficiency "A study indicated that the granisetron-transdermal system (GTDS) offered a novel, well-tolerated, and efficient approach of reducing nausea brought on by chemotherapy. If further research is done to gauge GTDS's efficacy, the market will expand dramatically. This study shows that granisetron can be used to treat the side effects of chemotherapy given to cancer patients. The growing number of cancer cases around the world will increase the demand for granisetron, which will help boost the market. Lung and prostrate cancer are more common in women than they are in men. Breast cancer is more common in women than it is among men. The high incidence of these diseases worldwide will have a positive impact on granisetron production and consumption, driving the market.
The study "Gastroparesis", published in National Center for Biotechnology Information, and updated, found that Granisetron, which is a 5-HT3 antagonist administered as a transdermal application, improved the symptoms of gastroparesis, including nausea and vomiting. The market growth is expected to be fueled by the results of studies that evaluate the effectiveness of granisetron in treating gastroparesis symptoms. The market studied is expected to expand significantly due to the factors mentioned above. The market growth will be slowed by the potential adverse effects of Granisetron. Market growth is being driven by the rising number of radiotherapy and chemotherapy visits, as well as the growing prevalence of gastroparesis. Market growth will be driven by the rising incidence of cancer.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Granisetron Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Granisetron Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.